Roche's Avastin forestalls progression, death in brain cancer study

11/19/2012 | CNBC

Roche Holding's Avastin, in combination with radiation and chemotherapy, lowered the risk of cancer progression or death in patients with a common form of brain cancer during a Phase III trial. The drug, however, failed to significantly improve overall survival rates. Avastin is approved for treatment of several cancers including kidney and breast cancers.

View Full Article in:

CNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX